-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Biogen, Raises Price Target to $215

Benzinga·07/30/2026 13:40:53
Listen to the news
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $201 to $215.